These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|
|
|||||||
(State or other jurisdiction of
incorporation or organization) |
(I.R.S. Employer
Identification No.) |
|
☒ | Accelerated filer |
☐
|
|||||||||||||||||
Non-accelerated filer |
☐
|
Smaller reporting company |
|
|||||||||||||||||
Emerging growth company |
|
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
|
|
|
Page
Number(s) |
||||||||
EXHIBITS |
Item 1. | Financial Statements (Unaudited). |
Three Months Ended
June 30, |
Six Months Ended
June 30, |
||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Net sales | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Cost of goods sold |
|
|
|
|
|||||||||||||||||||
Gross profit |
|
|
|
|
|||||||||||||||||||
Selling, general and administrative expenses |
|
|
|
|
|||||||||||||||||||
Research and development expenses |
|
|
|
|
|||||||||||||||||||
Gain on sale of business |
(
|
|
(
|
|
|||||||||||||||||||
Operating profit |
|
|
|
|
|||||||||||||||||||
Interest and financing expenses |
(
|
(
|
(
|
(
|
|||||||||||||||||||
Other income (expense), net |
|
(
|
|
|
|||||||||||||||||||
Income before income taxes and equity in net income of unconsolidated investments |
|
|
|
|
|||||||||||||||||||
Income tax expense |
|
|
|
|
|||||||||||||||||||
Income before equity in net income of unconsolidated investments |
|
|
|
|
|||||||||||||||||||
Equity in net income of unconsolidated investments (net of tax) |
|
|
|
|
|||||||||||||||||||
Net income |
|
|
|
|
|||||||||||||||||||
Net income attributable to noncontrolling interests |
(
|
(
|
(
|
(
|
|||||||||||||||||||
Net income attributable to Albemarle Corporation | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Basic earnings per share | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Diluted earnings per share | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Weighted-average common shares outstanding – basic |
|
|
|
|
|||||||||||||||||||
Weighted-average common shares outstanding – diluted |
|
|
|
|
Three Months Ended
June 30, |
Six Months Ended
June 30, |
||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Net income | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Other comprehensive income (loss), net of tax: | |||||||||||||||||||||||
Foreign currency translation and other |
|
|
(
|
(
|
|||||||||||||||||||
Net investment hedge |
|
(
|
|
(
|
|||||||||||||||||||
Cash flow hedge |
|
|
(
|
(
|
|||||||||||||||||||
Interest rate swap |
|
|
|
|
|||||||||||||||||||
Total other comprehensive income (loss), net of tax |
|
|
(
|
(
|
|||||||||||||||||||
Comprehensive income |
|
|
|
|
|||||||||||||||||||
Comprehensive income attributable to noncontrolling interests |
(
|
(
|
(
|
(
|
|||||||||||||||||||
Comprehensive income attributable to Albemarle Corporation | $ |
|
$ |
|
$ |
|
$ |
|
June 30, | December 31, | ||||||||||
2021 | 2020 | ||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents
|
$ |
|
$ |
|
|||||||
Trade accounts receivable, less allowance for doubtful accounts (2021 – $
|
|
|
|||||||||
Other accounts receivable |
|
|
|||||||||
Inventories |
|
|
|||||||||
Other current assets |
|
|
|||||||||
Total current assets |
|
|
|||||||||
Property, plant and equipment, at cost |
|
|
|||||||||
Less accumulated depreciation and amortization |
|
|
|||||||||
Net property, plant and equipment |
|
|
|||||||||
Investments |
|
|
|||||||||
Other assets |
|
|
|||||||||
Goodwill |
|
|
|||||||||
Other intangibles, net of amortization |
|
|
|||||||||
Total assets | $ |
|
$ |
|
|||||||
Liabilities And Equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ |
|
$ |
|
|||||||
Accrued expenses |
|
|
|||||||||
Current portion of long-term debt |
|
|
|||||||||
Dividends payable |
|
|
|||||||||
Income taxes payable |
|
|
|||||||||
Total current liabilities |
|
|
|||||||||
Long-term debt |
|
|
|||||||||
Postretirement benefits |
|
|
|||||||||
Pension benefits |
|
|
|||||||||
Other noncurrent liabilities |
|
|
|||||||||
Deferred income taxes |
|
|
|||||||||
Commitments and contingencies (Note 9) |
|
|
|||||||||
Equity: | |||||||||||
Albemarle Corporation shareholders’ equity: | |||||||||||
Common stock, $
|
|
|
|||||||||
Additional paid-in capital |
|
|
|||||||||
Accumulated other comprehensive loss |
(
|
(
|
|||||||||
Retained earnings |
|
|
|||||||||
Total Albemarle Corporation shareholders’ equity |
|
|
|||||||||
Noncontrolling interests |
|
|
|||||||||
Total equity |
|
|
|||||||||
Total liabilities and equity | $ |
|
$ |
|
(In Thousands, Except Share Data) |
Additional
Paid-in Capital |
Accumulated Other
Comprehensive Loss |
Retained Earnings |
Total Albemarle
Shareholders’ Equity |
Noncontrolling
Interests |
Total Equity | |||||||||||||||||||||||||||||||||||||||||
Common Stock | |||||||||||||||||||||||||||||||||||||||||||||||
Shares | Amounts | ||||||||||||||||||||||||||||||||||||||||||||||
Balance at April 1, 2021 |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||
Net income |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) |
|
|
(
|
|
|||||||||||||||||||||||||||||||||||||||||||
Cash dividends declared, $
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
Fees related to public issuance of common stock |
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock, net |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Shares withheld for withholding taxes associated with common stock issuances |
(
|
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2021 |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||
Balance at April 1, 2020 |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||
Net income |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||
Cash dividends declared, $
|
(
|
(
|
|
(
|
|||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock, net |
|
|
(
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Shares withheld for withholding taxes associated with common stock issuances |
(
|
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2020 |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||
Balance at January 1, 2021 |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||
Net income |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||
Other comprehensive loss |
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||||||||||||||||
Cash dividends declared, $
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
Fees related to public issuance of common stock |
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock, net |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Shares withheld for withholding taxes associated with common stock issuances |
(
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2021 |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||
Balance at January 1, 2020 |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||
Net income |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||
Other comprehensive (loss) income |
(
|
(
|
|
(
|
|||||||||||||||||||||||||||||||||||||||||||
Cash dividends declared, $
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock, net |
|
|
(
|
|
|
||||||||||||||||||||||||||||||||||||||||||
Shares withheld for withholding taxes associated with common stock issuances |
(
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2020 |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
Six Months Ended
June 30, |
|||||||||||
2021 | 2020 | ||||||||||
Cash and cash equivalents at beginning of year | $ |
|
$ |
|
|||||||
Cash flows from operating activities: | |||||||||||
Net income |
|
|
|||||||||
Adjustments to reconcile net income to cash flows from operating activities: | |||||||||||
Depreciation and amortization |
|
|
|||||||||
Gain on sale of business |
(
|
|
|||||||||
Stock-based compensation and other |
|
|
|||||||||
Equity in net income of unconsolidated investments (net of tax) |
(
|
(
|
|||||||||
Dividends received from unconsolidated investments and nonmarketable securities |
|
|
|||||||||
Pension and postretirement benefit |
(
|
(
|
|||||||||
Pension and postretirement contributions |
(
|
(
|
|||||||||
Unrealized gain on investments in marketable securities |
(
|
(
|
|||||||||
Loss on early extinguishment of debt |
|
|
|||||||||
Deferred income taxes |
|
|
|||||||||
Working capital changes |
|
(
|
|||||||||
Non-cash transfer of 40% value of construction in progress of Kemerton plant to MRL |
|
|
|||||||||
Other, net |
(
|
(
|
|||||||||
Net cash provided by operating activities |
|
|
|||||||||
Cash flows from investing activities: | |||||||||||
Acquisitions, net of cash acquired |
|
(
|
|||||||||
Capital expenditures |
(
|
(
|
|||||||||
Cash proceeds from divestitures, net |
|
|
|||||||||
Sales of marketable securities, net |
|
|
|||||||||
Investments in equity and other corporate investments |
(
|
(
|
|||||||||
Net cash used in investing activities |
(
|
(
|
|||||||||
Cash flows from financing activities: | |||||||||||
Proceeds from issuance of common stock |
|
|
|||||||||
Repayments of long-term debt and credit agreements |
(
|
|
|||||||||
Proceeds from borrowings of credit agreements |
|
|
|||||||||
Other debt repayments, net |
(
|
|
|||||||||
Fees related to early extinguishment of debt |
(
|
|
|||||||||
Dividends paid to shareholders |
(
|
(
|
|||||||||
Dividends paid to noncontrolling interests |
(
|
(
|
|||||||||
Proceeds from exercise of stock options |
|
|
|||||||||
Withholding taxes paid on stock-based compensation award distributions |
(
|
(
|
|||||||||
Other |
(
|
(
|
|||||||||
Net cash (used in) provided by financing activities |
(
|
|
|||||||||
Net effect of foreign exchange on cash and cash equivalents |
(
|
(
|
|||||||||
Increase in cash and cash equivalents |
|
|
|||||||||
Cash and cash equivalents at end of period | $ |
|
$ |
|
Lithium | Bromine Specialties | Catalysts | All Other | Total | |||||||||||||||||||||||||
Balance at December 31, 2020
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
Divestitures
(a)
|
|
|
|
(
|
(
|
||||||||||||||||||||||||
Foreign currency translation adjustments |
(
|
|
(
|
|
(
|
||||||||||||||||||||||||
Balance at June 30, 2021 | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
Customer Lists and Relationships |
Trade Names and Trademarks
(a)
|
Patents and Technology | Other | Total | |||||||||||||||||||||||||
Gross Asset Value | |||||||||||||||||||||||||||||
Balance at December 31, 2020
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
Divestitures
(b)
|
|
|
|
(
|
(
|
||||||||||||||||||||||||
Foreign currency translation adjustments and other |
(
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||||
Balance at June 30, 2021
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
Accumulated Amortization | |||||||||||||||||||||||||||||
Balance at December 31, 2020
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||
Amortization |
(
|
|
(
|
(
|
(
|
||||||||||||||||||||||||
Divestitures
(b)
|
|
|
|
|
|
||||||||||||||||||||||||
Foreign currency translation adjustments and other |
|
|
|
|
|
||||||||||||||||||||||||
Balance at June 30, 2021
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||
Net Book Value at December 31, 2020
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
Net Book Value at June 30, 2021
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
Three Months Ended
June 30, |
Six Months Ended
June 30, |
||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Basic earnings per share | |||||||||||||||||||||||
Numerator: | |||||||||||||||||||||||
Net income attributable to Albemarle Corporation | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Denominator: | |||||||||||||||||||||||
Weighted-average common shares for basic earnings per share |
|
|
|
|
|||||||||||||||||||
Basic earnings per share | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Diluted earnings per share | |||||||||||||||||||||||
Numerator: | |||||||||||||||||||||||
Net income attributable to Albemarle Corporation | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Denominator: | |||||||||||||||||||||||
Weighted-average common shares for basic earnings per share |
|
|
|
|
|||||||||||||||||||
Incremental shares under stock compensation plans |
|
|
|
|
|||||||||||||||||||
Weighted-average common shares for diluted earnings per share |
|
|
|
|
|||||||||||||||||||
Diluted earnings per share | $ |
|
$ |
|
$ |
|
$ |
|
June 30, | December 31, | ||||||||||
2021 | 2020 | ||||||||||
Finished goods | $ |
|
$ |
|
|||||||
Raw materials and work in process
(a)
|
|
|
|||||||||
Stores, supplies and other |
|
|
|||||||||
Total | $ |
|
$ |
|
June 30, | December 31, | ||||||||||
2021 | 2020 | ||||||||||
|
$ |
|
$ |
|
|||||||
|
|
|
|||||||||
|
|
|
|||||||||
|
|
|
|||||||||
|
|
|
|||||||||
|
|
|
|||||||||
Floating rate notes |
|
|
|||||||||
Credit facilities |
|
|
|||||||||
Commercial paper notes |
|
|
|||||||||
Variable-rate foreign bank loans |
|
|
|||||||||
Finance lease obligations |
|
|
|||||||||
Unamortized discount and debt issuance costs |
(
|
(
|
|||||||||
Total long-term debt |
|
|
|||||||||
Less amounts due within one year |
|
|
|||||||||
Long-term debt, less current portion | $ |
|
$ |
|
Beginning balance at December 31, 2020
|
$ |
|
|||
Expenditures |
(
|
||||
Accretion of discount |
|
||||
Additions and changes in estimates |
|
||||
Foreign currency translation adjustments and other |
(
|
||||
Ending balance at June 30, 2021
|
|
||||
Less amounts reported in Accrued expenses |
|
||||
Amounts reported in Other noncurrent liabilities | $ |
|
Three Months Ended
June 30, |
Six Months Ended
June 30, |
||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Operating lease cost | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Finance lease cost: | |||||||||||||||||||||||
Amortization of right of use assets |
|
|
|
|
|||||||||||||||||||
Interest on lease liabilities |
|
|
|
|
|||||||||||||||||||
Total finance lease cost |
|
|
|
|
|||||||||||||||||||
Short-term lease cost |
|
|
|
|
|||||||||||||||||||
Variable lease cost |
|
|
|
|
|||||||||||||||||||
Total lease cost | $ |
|
$ |
|
$ |
|
$ |
|
Six Months Ended June 30, | |||||||||||
2021 | 2020 | ||||||||||
Cash paid for amounts included in the measurement of lease liabilities: | |||||||||||
Operating cash flows from operating leases | $ |
|
$ |
|
|||||||
Operating cash flows from finance leases |
|
|
|||||||||
Financing cash flows from finance leases |
|
|
|||||||||
Right-of-use assets obtained in exchange for lease obligations: | |||||||||||
Operating leases |
|
|
|||||||||
June 30, 2021 | December 31, 2020 | ||||||||||
Operating leases: | |||||||||||
Other assets | $ |
|
$ |
|
|||||||
Accrued expenses |
|
|
|||||||||
Other noncurrent liabilities |
|
|
|||||||||
Total operating lease liabilities |
|
|
|||||||||
Finance leases: | |||||||||||
Net property, plant and equipment |
|
|
|||||||||
Current portion of long-term debt
(a)
|
|
|
|||||||||
Long-term debt |
|
|
|||||||||
Total finance lease liabilities |
|
|
|||||||||
Weighted average remaining lease term (in years): | |||||||||||
Operating leases |
|
|
|||||||||
Finance leases |
|
|
|||||||||
Weighted average discount rate (%): | |||||||||||
Operating leases |
|
% |
|
% | |||||||
Finance leases |
|
% |
|
% |
Operating Leases | Finance Leases | ||||||||||
Remainder of 2021 | $ |
|
$ |
|
|||||||
2022 |
|
|
|||||||||
2023 |
|
|
|||||||||
2024 |
|
|
|||||||||
2025 |
|
|
|||||||||
Thereafter |
|
|
|||||||||
Total lease payments |
|
|
|||||||||
Less imputed interest |
|
|
|||||||||
Total | $ |
|
$ |
|
Three Months Ended
June 30, |
Six Months Ended
June 30, |
||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
(In thousands) | (In thousands) | ||||||||||||||||||||||
Net sales: | |||||||||||||||||||||||
Lithium | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Bromine Specialties |
|
|
|
|
|||||||||||||||||||
Catalysts |
|
|
|
|
|||||||||||||||||||
All Other |
|
|
|
|
|||||||||||||||||||
Total net sales | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Adjusted EBITDA: | |||||||||||||||||||||||
Lithium | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Bromine Specialties |
|
|
|
|
|||||||||||||||||||
Catalysts |
|
|
|
|
|||||||||||||||||||
All Other |
|
|
|
|
|||||||||||||||||||
Corporate |
(
|
(
|
(
|
(
|
|||||||||||||||||||
Total adjusted EBITDA | $ |
|
$ |
|
$ |
|
$ |
|
Lithium | Bromine Specialties | Catalysts | Reportable Segments Total | All Other | Corporate | Consolidated Total | |||||||||||||||||||||||||||||||||||
Three months ended June 30, 2021 | |||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to Albemarle Corporation | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
Depreciation and amortization |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Restructuring and other
(a)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Gain on sale of business
(b)
|
|
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||||
Acquisition and integration related costs
(c)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Interest and financing expenses
(d)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Income tax expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Non-operating pension and OPEB items |
|
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||||
Albemarle Foundation contribution
(e)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Other
(f)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
Three months ended June 30, 2020 | |||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to Albemarle Corporation | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
Depreciation and amortization |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Restructuring and other
(a)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Acquisition and integration related costs
(c)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Interest and financing expenses |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Income tax expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Non-operating pension and OPEB items |
|
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||||
Other
(g)
|
|
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
Six months ended June 30, 2021 | |||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to Albemarle Corporation | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
Depreciation and amortization |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Restructuring and other
(a)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Gain on sale of business
(b)
|
|
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||||
Acquisition and integration related costs
(c)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Interest and financing expenses
(d)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Income tax expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Non-operating pension and OPEB items |
|
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||||
Albemarle Foundation contribution
(e)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Other
(f)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
Six months ended June 30, 2020 | |||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to Albemarle Corporation | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||||||||
Depreciation and amortization |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Restructuring and other
(a)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Acquisition and integration related costs
(c)
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Interest and financing expenses |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Income tax expense |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
Non-operating pension and OPEB items |
|
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||||
Other
(g)
|
|
|
|
|
|
(
|
(
|
||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
Three Months Ended
June 30, |
Six Months Ended
June 30, |
||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Pension Benefits Cost (Credit): | |||||||||||||||||||||||
Service cost | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Interest cost |
|
|
|
|
|||||||||||||||||||
Expected return on assets |
(
|
(
|
(
|
(
|
|||||||||||||||||||
Amortization of prior service benefit |
|
|
|
|
|||||||||||||||||||
Total net pension benefits credit | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||
Postretirement Benefits Cost: | |||||||||||||||||||||||
Service cost | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Interest cost |
|
|
|
|
|||||||||||||||||||
Total net postretirement benefits cost | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Total net pension and postretirement benefits credit | $ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
June 30, 2021 | December 31, 2020 | ||||||||||||||||||||||
Recorded
Amount |
Fair Value |
Recorded
Amount |
Fair Value | ||||||||||||||||||||
(In thousands) | |||||||||||||||||||||||
Long-term debt | $ |
|
$ |
|
$ |
|
$ |
|
June 30, 2021 | December 31, 2020 | ||||||||||||||||||||||
Assets | Liabilities | Assets | Liabilities | ||||||||||||||||||||
Designated as hedging instruments
(a)
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Not Designated as hedging instruments
(b)
|
|
|
|
|
|||||||||||||||||||
Total | $ |
|
$ |
|
$ |
|
$ |
|
Three Months Ended
June 30, |
Six Months Ended
June 30, |
||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Designated as hedging instruments | |||||||||||||||||||||||
Income (loss) recognized in Other comprehensive income (loss) | $ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||
Not designated as hedging instruments | |||||||||||||||||||||||
Income (loss) recognized in Other income (expense), net
(a)
|
$ |
|
$ |
(
|
$ |
|
$ |
(
|
Level 1 | Unadjusted quoted prices in active markets for identical assets or liabilities | ||||
Level 2 | Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability | ||||
Level 3 | Unobservable inputs for the asset or liability |
June 30, 2021 | Quoted Prices in Active Markets for Identical Items (Level 1) | Quoted Prices in Active Markets for Similar Items (Level 2) | Unobservable Inputs (Level 3) | ||||||||||||||||||||
Assets: | |||||||||||||||||||||||
Available for sale debt securities
(a)
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Investments under executive deferred compensation plan
(b)
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Private equity securities measured at net asset value
(c)(d)
|
$ |
|
$ | — | $ | — | $ | — | |||||||||||||||
Foreign currency forward contracts
(e)
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Liabilities: | |||||||||||||||||||||||
Obligations under executive deferred compensation plan
(b)
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Foreign currency forward contracts
(e)
|
$ |
|
$ |
|
$ |
|
$ |
|
December 31, 2020 | Quoted Prices in Active Markets for Identical Items (Level 1) | Quoted Prices in Active Markets for Similar Items (Level 2) | Unobservable Inputs (Level 3) | ||||||||||||||||||||
Assets: | |||||||||||||||||||||||
Investments under executive deferred compensation plan
(b)
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Private equity securities measured at net asset value
(c)(d)
|
$ |
|
$ | — | $ | — | $ | — | |||||||||||||||
Foreign currency forward contracts
(e)
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Liabilities: | |||||||||||||||||||||||
Obligations under executive deferred compensation plan
(b)
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Foreign currency forward contracts
(e)
|
$ |
|
$ |
|
$ |
|
$ |
|
Available for Sale Debt Securities | |||||
Beginning balance at December 31, 2020 | $ |
|
|||
Additions | 244,530 | ||||
Ending balance at June 30, 2021 | $ |
|
Foreign Currency Translation and Other |
Net Investment Hedge
(a)
|
Cash Flow Hedge
(b)
|
Interest Rate Swap
(c)
|
Total | |||||||||||||||||||||||||||||||||||||
Three months ended June 30, 2021 | |||||||||||||||||||||||||||||||||||||||||
Balance at March 31, 2021 | $ |
(
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||||||||
Other comprehensive income before reclassifications |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
Amounts reclassified from accumulated other comprehensive loss |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
Other comprehensive income, net of tax |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
Other comprehensive income attributable to noncontrolling interests |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
Balance at June 30, 2021 | $ |
(
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||||||||
Three months ended June 30, 2020 | |||||||||||||||||||||||||||||||||||||||||
Balance at March 31, 2020 | $ |
(
|
$ |
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||||||||
Other comprehensive income (loss) before reclassifications |
|
(
|
|
|
|
||||||||||||||||||||||||||||||||||||
Amounts reclassified from accumulated other comprehensive loss |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss), net of tax |
|
(
|
|
|
|
||||||||||||||||||||||||||||||||||||
Other comprehensive loss attributable to noncontrolling interests |
(
|
|
|
|
(
|
||||||||||||||||||||||||||||||||||||
Balance at June 30, 2020 | $ |
(
|
$ |
|
$ |
(
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||||||||
Six months ended June 30, 2021 | |||||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2020 | $ |
(
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||||||||
Other comprehensive (loss) income before reclassifications |
(
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||||||||
Amounts reclassified from accumulated other comprehensive loss |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
Other comprehensive (loss) income, net of tax |
(
|
|
(
|
|
(
|
||||||||||||||||||||||||||||||||||||
Amounts reclassified within accumulated other comprehensive loss |
|
(
|
|
|
|
||||||||||||||||||||||||||||||||||||
Other comprehensive income attributable to noncontrolling interests |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
Balance at June 30, 2021 | $ |
(
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||||||||
Six months ended June 30, 2020 | |||||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2019 | $ |
(
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|||||||||||||||||||||||||||||||
Other comprehensive loss before reclassifications |
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||||||||
Amounts reclassified from accumulated other comprehensive loss |
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
Other comprehensive (loss) income, net of tax |
(
|
(
|
(
|
|
(
|
||||||||||||||||||||||||||||||||||||
Other comprehensive loss attributable to noncontrolling interests |
(
|
|
|
|
(
|
||||||||||||||||||||||||||||||||||||
Balance at June 30, 2020 | $ |
(
|
$ |
|
$ |
(
|
$ |
(
|
$ |
(
|
Foreign Currency Translation and Other | Net Investment Hedge | Cash Flow Hedge | Interest Rate Swap | ||||||||||||||||||||||||||
Three months ended June 30, 2021 | |||||||||||||||||||||||||||||
Other comprehensive income, before tax | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||
Income tax expense |
(
|
|
|
(
|
|||||||||||||||||||||||||
Other comprehensive income, net of tax | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||
Three months ended June 30, 2020 | |||||||||||||||||||||||||||||
Other comprehensive income (loss), before tax | $ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||||||||
Income tax (expense) benefit |
(
|
|
|
(
|
|||||||||||||||||||||||||
Other comprehensive income (loss), net of tax | $ |
|
$ |
(
|
$ |
|
$ |
|
|||||||||||||||||||||
Six months ended June 30, 2021 | |||||||||||||||||||||||||||||
Other comprehensive (loss) income, before tax | $ |
(
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||
Income tax (expense) |
(
|
(
|
|
(
|
|||||||||||||||||||||||||
Other comprehensive (loss) income, net of tax | $ |
(
|
$ |
|
$ |
(
|
$ |
|
|||||||||||||||||||||
Six months ended June 30, 2020 | |||||||||||||||||||||||||||||
Other comprehensive (loss) income, before tax | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
|||||||||||||||||||||
Income tax benefit (expense) |
|
|
|
(
|
|||||||||||||||||||||||||
Other comprehensive (loss) income, net of tax | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
Three Months Ended
June 30, |
Six Months Ended
June 30, |
||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | ||||||||||||||||||||
Sales to unconsolidated affiliates | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Purchases from unconsolidated affiliates
(a)
|
$ |
|
$ |
|
$ |
|
$ |
|
June 30, 2021 | December 31, 2020 | ||||||||||
Receivables from unconsolidated affiliates | $ |
|
$ |
|
|||||||
Payables to unconsolidated affiliates | $ |
|
$ |
|
Six Months Ended
June 30, |
|||||||||||
2021 | 2020 | ||||||||||
Supplemental non-cash disclosure related to investing activities: | |||||||||||
Capital expenditures included in Accounts payable | $ |
|
$ |
|
|||||||
Non-cash proceeds from divestitures
(a)
|
$ |
|
$ |
|
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Net sales | $ | 773,896 | $ | 764,049 | $ | 9,847 | 1 | % | |||||||||||||||
▪
$25.0 million decrease in net sales resulting from the sale of the FCS business on June 1, 2021
▪
$21.6 million of higher sales volume in Lithium and Bromine Specialties, partially offset by Catalysts
▪
Pricing was essentially flat, primarily driven by lower Lithium pricing, offset by Bromine Specialties
▪
$13.1 million of favorable currency translation resulting from the weaker U.S. Dollar against various currencies
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Gross profit | $ | 248,417 | $ | 233,359 | $ | 15,058 | 6 | % | |||||||||||||||
Gross profit margin | 32.1 | % | 30.5 | % | |||||||||||||||||||
▪
Higher sales volume in Lithium and Bromine Specialties, partially offset by unfavorable pricing in Lithium
▪
Lower commission expenses in Chile resulting from the lower pricing in Lithium
▪
Decrease in net sales resulting from the disposal of the FCS business on June 1, 2021
▪
The second quarter of 2020 included $9.8 million of additional expense in Cost of goods sold related to the correction of errors regarding inventory values and overstated freight costs primarily from the first quarter of 2020
▪
Increased freight costs in Bromine Specialties and Catalysts
▪
Favorable currency exchange impacts resulting from the weaker U.S. Dollar against various currencies
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Selling, general and administrative expenses | $ | 121,516 | $ | 106,949 | $ | 14,567 | 14 | % | |||||||||||||||
Percentage of Net sales | 15.7 | % | 14.0 | % | |||||||||||||||||||
▪
$20.0 million charitable contribution, using a portion of the proceeds received from the FCS divestiture, to the Albemarle Foundation, in addition to the normal annual contributions in 2021
▪
$4.0 million loss resulting from the sale of property, plant and equipment in 2021
▪
Increase in Corporate costs primarily related to higher incentive compensation
▪
Partially offset by productivity improvements and a reduction in professional fees and other administrative costs
▪
$9.5 million decrease in restructuring and other expenses and acquisition and integration related costs for various significant projects
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Research and development expenses | $ | 13,976 | $ | 14,210 | $ | (234) | (2) | % | |||||||||||||||
Percentage of Net sales | 1.8 | % | 1.9 | % | |||||||||||||||||||
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Gain on sale of business | $ | (429,408) | $ | — | $ | (429,408) | |||||||||||||||||
▪
Gain resulting from sale of FCS business on June 1, 2021
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Interest and financing expenses | $ | (7,152) | $ | (17,852) | $ | 10,700 | (60) | % | |||||||||||||||
▪
Decreased debt balance as certain debt instruments were repaid in the first quarter of 2021
▪
Higher capitalized interest from continued capital expenditures in 2021
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Other income, net | $ | 14 | $ | (6,273) | $ | 6,287 | (100) | % | |||||||||||||||
•
$6.9 million decrease in foreign exchange losses
•
$2.6 million increase in non-operating pension and OPEB benefits
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Income tax expense | $ | 106,985 | $ | 15,431 | $ | 91,554 | 593 | % | |||||||||||||||
Effective income tax rate
|
20.0 | % | 17.5 | % | |||||||||||||||||||
•
$97.8 million one-time tax expense recorded for the gain on the sale of the FCS business in 2021
•
Change in geographic mix of earnings, mainly attributable to our share of the income of our Jordan Bromine
Company Limited (“JBC”) joint venture, a Free Zones company under the laws of the Hashemite Kingdom of
Jordan
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Equity in net income of unconsolidated investments | $ | 17,998 | $ | 31,114 | $ | (13,116) | (42) | % | |||||||||||||||
▪
Primarily lower earnings from our Lithium segment joint venture, Windfield Holdings Pty Ltd (“Talison”), primarily driven by lower pricing and unfavorable foreign exchange impacts, partially offset by higher volumes
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Net income attributable to noncontrolling interests | $ | (21,608) | $ | (18,134) | $ | (3,474) | 19 | % | |||||||||||||||
▪
Increase in consolidated income related to our JBC joint venture from higher sales volume
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Net income attributable to Albemarle Corporation | $ | 424,600 | $ | 85,624 | $ | 338,976 | 396 | % | |||||||||||||||
Percentage of Net sales | 54.9 | % | 11.2 | % | |||||||||||||||||||
Basic earnings per share | $ | 3.63 | $ | 0.81 | $ | 2.82 | 348 | % | |||||||||||||||
Diluted earnings per share | $ | 3.62 | $ | 0.80 | $ | 2.82 | 353 | % | |||||||||||||||
▪
Gain on sale of FCS business of $331.6 million, net of tax
▪
Increased sales volume from Lithium and Bromine Specialties, partially offset by unfavorable pricing in Lithium
▪
Lower commission expenses in Chile resulting from the lower pricing in Lithium
▪
Decreased interest and financing expenses due to lower debt balances
▪
Productivity improvements and a reduction in professional fees and other administrative costs
▪
Loss of month of sales from FCS business following the disposition on June 1, 2021
▪
Increased SG&A expenses, primarily related to additional charitable contribution using proceeds from the sale of the FCS business
▪
Lower equity in net income of unconsolidated investments from the Talison joint venture
▪
Earnings per share also impacted by the underwritten public offering of our common stock in February 2021, increasing share count by 9.8 million shares
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Other comprehensive income (loss), net of tax | $ | 22,037 | $ | 95,392 | $ | (73,355) | (77) | % | |||||||||||||||
▪
Foreign currency translation and other
|
$ | 20,564 | $ | 62,855 | $ | (42,291) | (67) | % | |||||||||||||||
▪
2021 included favorable movements in the Brazilian Real of approximately $11 million, the Chinese Renminbi of $5 million and a net favorable variance in various other currencies of $5 million
▪
2020 included favorable movements in the Euro of approximately $60 million and a net unfavorable variance in various other currencies totaling approximately $7 million, partially offset by unfavorable movements in the Brazilian Real of approximately $4 million
|
|||||||||||||||||||||||
▪
Cash flow hedge
|
$ | 823 | $ | 37,645 | $ | (36,822) | |||||||||||||||||
▪
Net investment hedge
|
$ | — | $ | (5,756) | $ | 5,756 | (100) | % |
Three Months Ended June 30, | Percentage Change | ||||||||||||||||||||||||||||
2021 | % | 2020 | % | 2021 vs 2020 | |||||||||||||||||||||||||
(In thousands, except percentages) | |||||||||||||||||||||||||||||
Net sales: | |||||||||||||||||||||||||||||
Lithium | $ | 320,334 | 41.4 | % | $ | 283,722 | 37.1 | % | 13 | % | |||||||||||||||||||
Bromine Specialties | 279,748 | 36.1 | % | 232,779 | 30.5 | % | 20 | % | |||||||||||||||||||||
Catalysts | 148,344 | 19.2 | % | 197,053 | 25.8 | % | (25) | % | |||||||||||||||||||||
All Other | 25,470 | 3.3 | % | 50,495 | 6.6 | % | (50) | % | |||||||||||||||||||||
Total net sales | $ | 773,896 | 100.0 | % | $ | 764,049 | 100.0 | % | 1 | % | |||||||||||||||||||
Adjusted EBITDA: | |||||||||||||||||||||||||||||
Lithium | $ | 109,441 | 56.2 | % | $ | 94,536 | 51.0 | % | 16 | % | |||||||||||||||||||
Bromine Specialties | 92,646 | 47.6 | % | 73,041 | 39.4 | % | 27 | % | |||||||||||||||||||||
Catalysts | 21,164 | 10.9 | % | 22,777 | 12.3 | % | (7) | % | |||||||||||||||||||||
All Other | 8,379 | 4.3 | % | 18,598 | 10.1 | % | (55) | % | |||||||||||||||||||||
Corporate | (37,002) | (19.0) | % | (23,759) | (12.8) | % | (56) | % | |||||||||||||||||||||
Total adjusted EBITDA | $ | 194,628 | 100.0 | % | $ | 185,193 | 100.0 | % | 5 | % |
Lithium | Bromine Specialties | Catalysts | Reportable Segments Total | All Other | Corporate | Consolidated Total | |||||||||||||||||||||||||||||||||||
Three months ended June 30, 2021 | |||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to Albemarle Corporation | $ | 74,593 | $ | 80,148 | $ | 8,446 | $ | 163,187 | $ | 7,972 | $ | 253,441 | $ | 424,600 | |||||||||||||||||||||||||||
Depreciation and amortization | 33,497 | 12,498 | 12,718 | 58,713 | 407 | 2,303 | 61,423 | ||||||||||||||||||||||||||||||||||
Restructuring and other
(a)
|
— | — | — | — | — | 766 | 766 | ||||||||||||||||||||||||||||||||||
Gain on sale of business
(b)
|
— | — | — | — | — | (429,408) | (429,408) | ||||||||||||||||||||||||||||||||||
Acquisition and integration related costs
(c)
|
— | — | — | — | — | 1,915 | 1,915 | ||||||||||||||||||||||||||||||||||
Interest and financing expenses
(d)
|
— | — | — | — | — | 7,152 | 7,152 | ||||||||||||||||||||||||||||||||||
Income tax expense | — | — | — | — | — | 106,985 | 106,985 | ||||||||||||||||||||||||||||||||||
Non-operating pension and OPEB items | — | — | — | — | — | (5,471) | (5,471) | ||||||||||||||||||||||||||||||||||
Albemarle Foundation contribution
(e)
|
— | — | — | — | — | 20,000 | 20,000 | ||||||||||||||||||||||||||||||||||
Other
(f)
|
1,351 | — | — | 1,351 | — | 5,315 | 6,666 | ||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ | 109,441 | $ | 92,646 | $ | 21,164 | $ | 223,251 | $ | 8,379 | $ | (37,002) | $ | 194,628 | |||||||||||||||||||||||||||
Three months ended June 30, 2020 | |||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to Albemarle Corporation | $ | 66,038 | $ | 60,692 | $ | 10,702 | $ | 137,432 | $ | 16,425 | $ | (68,233) | $ | 85,624 | |||||||||||||||||||||||||||
Depreciation and amortization | 28,498 | 12,349 | 12,075 | 52,922 | 2,173 | 2,746 | 57,841 | ||||||||||||||||||||||||||||||||||
Restructuring and other
(a)
|
— | — | — | — | — | 6,733 | 6,733 | ||||||||||||||||||||||||||||||||||
Acquisition and integration related costs
(c)
|
— | — | — | — | — | 5,470 | 5,470 | ||||||||||||||||||||||||||||||||||
Gain on sale of property | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||
Interest and financing expenses | — | — | — | — | — | 17,852 | 17,852 | ||||||||||||||||||||||||||||||||||
Income tax expense | — | — | — | — | — | 15,431 | 15,431 | ||||||||||||||||||||||||||||||||||
Non-operating pension and OPEB items | — | — | — | — | — | (2,895) | (2,895) | ||||||||||||||||||||||||||||||||||
Other
(g)
|
— | — | — | — | — | (863) | (863) | ||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ | 94,536 | $ | 73,041 | $ | 22,777 | $ | 190,354 | $ | 18,598 | $ | (23,759) | $ | 185,193 |
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Net sales | $ | 320,334 | $ | 283,722 | $ | 36,612 | 13 | % | |||||||||||||||
▪
$47.1 million of higher sales volume, driven by some customers accelerating orders under long-term commitments in hydroxide
▪
$18.1 million of unfavorable pricing impacts, primarily in battery- and tech-grade carbonate and hydroxide due to lower contract pricing
▪
$7.6 million of favorable currency translation resulting from the weaker U.S. Dollar against various currencies
|
|||||||||||||||||||||||
Adjusted EBITDA | $ | 109,441 | $ | 94,536 | $ | 14,905 | 16 | % | |||||||||||||||
▪
Higher sales volume, partially offset by unfavorable pricing impacts
▪
Higher spodumene volumes at the Talison joint venture
▪
Lower commission expenses in Chile resulting from the lower pricing in Lithium
▪
Productivity improvements and a reduction in professional fees and other administrative costs
▪
$4.5 million of unfavorable currency translation resulting from a stronger Chilean Peso
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Net sales | $ | 279,748 | $ | 232,779 | $ | 46,969 | 20 | % | |||||||||||||||
▪
$26.0 million of higher sales volume related to increased demand across all products
▪
$17.2 million of favorable pricing impacts, primarily in the flame retardants division
▪
$3.7 million of favorable currency translation resulting from the weaker U.S. Dollar against various currencies
|
|||||||||||||||||||||||
Adjusted EBITDA | $ | 92,646 | $ | 73,041 | $ | 19,605 | 27 | % | |||||||||||||||
▪
Higher sales volume and favorable pricing impacts as a result of a favorable first quarter 2021 customer mix
▪
Productivity improvements and a reduction in professional fees and other administrative costs
▪
Increased freight costs
▪
$3.3 million of favorable currency translation resulting from the weaker U.S. Dollar against various currencies
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Net sales | $ | 148,344 | $ | 197,053 | $ | (48,709) | (25) | % | |||||||||||||||
▪
$51.5 million of lower sales volume, primarily from clean fuel technologies due to timing of shipments
▪
$0.9 million of favorable pricing impacts, primarily in PCS, partially offset by FCC
▪
$1.8 million of favorable currency translation resulting from the weaker U.S. Dollar against various currencies
|
|||||||||||||||||||||||
Adjusted EBITDA | $ | 21,164 | $ | 22,777 | $ | (1,613) | (7) | % | |||||||||||||||
▪
Lower sales volume, primarily from clean fuel technologies due to timing of shipments
▪
Increased freight costs
▪
The second quarter of 2020 included $12.0 million of additional expense related to the correction of errors primarily regarding inventory values and overstated freight costs primarily from the first quarter of 2020
▪
Partially offset by productivity improvements and a reduction in professional fees and other administrative costs
▪
Favorable PCS volume and price
▪
$1.1 million of unfavorable currency translation resulting from the stronger U.S. Dollar against various currencies
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Net sales | $ | 25,470 | $ | 50,495 | $ | (25,025) | (50) | % | |||||||||||||||
▪
Decreased volume resulting from the sale of the FCS business in the second quarter of 2021
|
|||||||||||||||||||||||
Adjusted EBITDA | $ | 8,379 | $ | 18,598 | $ | (10,219) | (55) | % | |||||||||||||||
▪
Decreased volume resulting from the sale of the FCS business in the second quarter of 2021
|
In thousands | Q2 2021 | Q2 2020 | $ Change | % Change | |||||||||||||||||||
Adjusted EBITDA | $ | (37,002) | $ | (23,759) | $ | (13,243) | (56) | % | |||||||||||||||
▪
$6.1 million of unfavorable currency exchange impacts, including a $13.0 million decrease in foreign exchange impacts from our Talison joint venture
▪
Increase in incentive compensation costs
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Net sales | $ | 1,603,187 | $ | 1,502,894 | $ | 100,293 | 7 | % | |||||||||||||||
▪
$38.5 million decrease in net sales from the FCS business, which was sold on June 1, 2021
▪
$135.9 million of higher sales volume from reportable segments, primarily in Lithium and Bromine Specialties, partially offset by Catalysts
▪
$27.1 million of unfavorable pricing from reportable segments, primarily driven by Lithium, partially offset by Bromine Specialties
▪
$30.1 million of favorable currency translation resulting from the weaker U.S. Dollar against various currencies
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Gross profit | $ | 512,104 | $ | 475,377 | $ | 36,727 | 8 | % | |||||||||||||||
Gross profit margin | 31.9 | % | 31.6 | % | |||||||||||||||||||
▪
Higher sales volume in Lithium and Bromine Specialties, partially offset by unfavorable pricing in Lithium
▪
Lower commission expenses in Chile resulting from the lower pricing in Lithium
▪
Decrease in net sales resulting from the disposal of the FCS business on June 1, 2021
▪
Increased production and utility costs of approximately $23 million in Bromine Specialties and Catalysts resulting from the U.S. Gulf Coast winter storm
▪
Increased freight costs in Bromine Specialties and Catalysts
▪
Favorable currency exchange impacts resulting from the weaker U.S. Dollar against various currencies
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Selling, general and administrative expenses | $ | 214,703 | $ | 208,826 | $ | 5,877 | 3 | % | |||||||||||||||
Percentage of Net sales | 13.4 | % | 13.9 | % | |||||||||||||||||||
▪
$20.0 million charitable contribution, using a portion of the proceeds received from the FCS divestiture, to the Albemarle Foundation, in addition to the normal annual contributions in 2021
▪
$6.0 million of expenses in 2021 primarily related to non-routine labor and compensation related costs that are outside normal compensation arrangements
▪
$4.0 million loss resulting from the sale of property, plant and equipment
▪
Partially offset by productivity improvements and a reduction in professional fees and other administrative costs
▪
$11.0 million decrease in restructuring and other expenses, and acquisition and integration related costs for various significant projects
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Research and development expenses | $ | 28,612 | $ | 30,307 | $ | (1,695) | (6) | % | |||||||||||||||
Percentage of Net sales | 1.8 | % | 2.0 | % | |||||||||||||||||||
▪
Decreased research and development spend in each of the reportable segments
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Gain on sale of business | $ | (429,408) | $ | — | $ | (429,408) | |||||||||||||||||
▪
Gain resulting from sale of FCS business on June 1, 2021
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Interest and financing expenses | $ | (51,034) | $ | (34,737) | $ | (16,297) | 47 | % | |||||||||||||||
▪
$29.0 million loss on early extinguishment of debt, representing the tender premiums, fees, unamortized discounts and unamortized deferred financing costs from the redemption of debt during the first quarter of 2021
▪
Partially offset by decreased debt balance as certain debt instruments were repaid in the first quarter of 2021
▪
Higher capitalized interest from continued capital expenditures in 2021
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Other income, net | $ | 11,326 | $ | 2,041 | $ | 9,285 | 455 | % | |||||||||||||||
•
$9.8 million decrease in foreign exchange losses
•
$5.1 million increase in non-operating pension and OPEB benefits
•
$3.6 million expense related to asset retirement obligation charges in 2021
•
$2.7 million gain resulting from the settlement of legal matters in 2020
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Income tax expense | $ | 129,092 | $ | 33,873 | $ | 95,219 | 281 | % | |||||||||||||||
Effective income tax rate
|
19.6 | % | 16.6 | % | |||||||||||||||||||
•
$97.8 million one-time tax expense recorded for the gain on the sale of the FCS business in 2021
•
Change in geographic mix of earnings, mainly attributable to our share of the income of our Jordan Bromine
Company Limited (“JBC”) joint venture, a Free Zones company under the laws of the Hashemite Kingdom of
Jordan
•
2021 includes certain discrete tax benefits, partially offset by expense due to an out-of-period adjustment for an overstated deferred tax liability recorded during the three-month period ended December 31, 2017
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Equity in net income of unconsolidated investments | $ | 34,509 | $ | 57,718 | $ | (23,209) | (40) | % | |||||||||||||||
▪
Primarily lower earnings from our Lithium segment joint venture, Talison, primarily driven by lower pricing and unfavorable foreign exchange impacts, partially offset by higher volumes
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Net income attributable to noncontrolling interests | $ | (43,629) | $ | (34,565) | $ | (9,064) | 26 | % | |||||||||||||||
▪
Increase in consolidated income related to our JBC joint venture from higher sales volume
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Net income attributable to Albemarle Corporation | $ | 520,277 | $ | 192,828 | $ | 327,449 | 170 | % | |||||||||||||||
Percentage of Net sales | 32.5 | % | 12.8 | % | |||||||||||||||||||
Basic earnings per share | $ | 4.54 | $ | 1.81 | $ | 2.73 | 151 | % | |||||||||||||||
Diluted earnings per share | $ | 4.51 | $ | 1.81 | $ | 2.70 | 149 | % | |||||||||||||||
▪
Gain on sale of FCS business of $331.6 million, net of tax
▪
Increased sales volume from Lithium and Bromine Specialties, partially offset by unfavorable pricing in Lithium
▪
Lower commission expenses in Chile resulting from the lower pricing in Lithium
▪
Decreased interest and financing expenses due to lower debt balances
▪
Productivity improvements and a reduction in professional fees and other administrative costs
▪
Loss of month of sales from FCS business following the disposition on June 1, 2021
▪
Increased production and utility costs in Bromine Specialties and Catalysts resulting from the winter storms in the southern U.S.
▪
Increased SG&A expenses, primarily related to additional charitable contribution using proceeds from the sale of the FCS business
▪
Lower equity in net income of unconsolidated investments from the Talison joint venture
▪
Earnings per share also impacted by the underwritten public offering of our common stock in February 2021, increasing share count by 9.8 million shares
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Other comprehensive income (loss), net of tax | $ | (1,945) | $ | (35,316) | $ | 33,371 | (94) | % | |||||||||||||||
▪
Foreign currency translation and other
|
$ | (7,578) | $ | (19,122) | $ | 11,544 | (60) | % | |||||||||||||||
▪
2021 included unfavorable movements in the Euro of approximately $11 million and the Japanese Yen of approximately $5 million, partially offset by favorable movements in the Brazilian Real of approximately $5 million and the Chinese Remninbi of approximately $4 million
▪
2020 included unfavorable movements in the Brazilian Real of approximately $20 million, and a net unfavorable movement in various other currencies totaling approximately $4 million, partially offset by favorable movements in the Euro of approximately $5 million
|
|||||||||||||||||||||||
▪
Cash flow hedge
|
$ | (777) | $ | (13,815) | $ | 13,038 | |||||||||||||||||
▪
Net investment hedge
|
$ | 5,110 | $ | (3,675) | $ | 8,785 | (239) | % |
Six Months Ended June 30, | Percentage Change | ||||||||||||||||||||||||||||
2021 | % | 2020 | % | 2021 vs 2020 | |||||||||||||||||||||||||
(In thousands, except percentages) | |||||||||||||||||||||||||||||
Net sales: | |||||||||||||||||||||||||||||
Lithium | $ | 599,310 | 37.4 | % | $ | 520,540 | 34.6 | % | 15 | % | |||||||||||||||||||
Bromine Specialties | 560,195 | 34.9 | % | 464,371 | 30.9 | % | 21 | % | |||||||||||||||||||||
Catalysts | 368,587 | 23.0 | % | 404,260 | 26.9 | % | (9) | % | |||||||||||||||||||||
All Other | 75,095 | 4.7 | % | 113,723 | 7.6 | % | (34) | % | |||||||||||||||||||||
Total net sales | $ | 1,603,187 | 100.0 | % | $ | 1,502,894 | 100.0 | % | 7 | % | |||||||||||||||||||
Adjusted EBITDA: | |||||||||||||||||||||||||||||
Lithium | $ | 215,877 | 50.8 | % | $ | 173,173 | 45.4 | % | 25 | % | |||||||||||||||||||
Bromine Specialties | 187,286 | 44.1 | % | 156,303 | 41.0 | % | 20 | % | |||||||||||||||||||||
Catalysts | 46,591 | 11.0 | % | 70,247 | 18.4 | % | (34) | % | |||||||||||||||||||||
All Other | 29,858 | 7.0 | % | 41,422 | 10.8 | % | (28) | % | |||||||||||||||||||||
Corporate | (54,930) | (12.9) | % | (59,587) | (15.6) | % | 8 | % | |||||||||||||||||||||
Total adjusted EBITDA | $ | 424,682 | 100.0 | % | $ | 381,558 | 100.0 | % | 11 | % |
Lithium | Bromine Specialties | Catalysts | Reportable Segments Total | All Other | Corporate | Consolidated Total | |||||||||||||||||||||||||||||||||||
Six months ended June 30, 2021 | |||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to Albemarle Corporation | $ | 144,965 | $ | 162,261 | $ | 21,362 | $ | 328,588 | $ | 27,988 | $ | 163,701 | $ | 520,277 | |||||||||||||||||||||||||||
Depreciation and amortization | 65,303 | 25,025 | 25,229 | 115,557 | 1,870 | 6,256 | 123,683 | ||||||||||||||||||||||||||||||||||
Restructuring and other
(a)
|
— | — | — | — | — | 1,540 | 1,540 | ||||||||||||||||||||||||||||||||||
Gain on sale of business
(b)
|
— | — | — | — | — | (429,408) | (429,408) | ||||||||||||||||||||||||||||||||||
Acquisition and integration related costs
(c)
|
— | — | — | — | — | 4,076 | 4,076 | ||||||||||||||||||||||||||||||||||
Interest and financing expenses
(d)
|
— | — | — | — | — | 51,034 | 51,034 | ||||||||||||||||||||||||||||||||||
Income tax expense | — | — | — | — | — | 129,092 | 129,092 | ||||||||||||||||||||||||||||||||||
Non-operating pension and OPEB items | — | — | — | — | — | (10,936) | (10,936) | ||||||||||||||||||||||||||||||||||
Albemarle Foundation contribution
(e)
|
— | — | — | — | — | 20,000 | 20,000 | ||||||||||||||||||||||||||||||||||
Other
(f)
|
5,609 | — | — | 5,609 | — | 9,715 | 15,324 | ||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ | 215,877 | $ | 187,286 | $ | 46,591 | $ | 449,754 | $ | 29,858 | $ | (54,930) | $ | 424,682 | |||||||||||||||||||||||||||
Six months ended June 30, 2020 | |||||||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to Albemarle Corporation | $ | 119,278 | $ | 132,357 | $ | 45,594 | $ | 297,229 | $ | 37,271 | $ | (141,672) | $ | 192,828 | |||||||||||||||||||||||||||
Depreciation and amortization | 53,895 | 23,946 | 24,653 | 102,494 | 4,151 | 4,890 | 111,535 | ||||||||||||||||||||||||||||||||||
Restructuring and other
(a)
|
— | — | — | — | — | 8,580 | 8,580 | ||||||||||||||||||||||||||||||||||
Acquisition and integration related costs
(b)
|
— | — | — | — | — | 8,426 | 8,426 | ||||||||||||||||||||||||||||||||||
Interest and financing expenses | — | — | — | — | — | 34,737 | 34,737 | ||||||||||||||||||||||||||||||||||
Income tax expense | — | — | — | — | — | 33,873 | 33,873 | ||||||||||||||||||||||||||||||||||
Non-operating pension and OPEB items | — | — | — | — | — | (5,803) | (5,803) | ||||||||||||||||||||||||||||||||||
Other
(g)
|
— | — | — | — | — | (2,618) | (2,618) | ||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ | 173,173 | $ | 156,303 | $ | 70,247 | $ | 399,723 | $ | 41,422 | $ | (59,587) | $ | 381,558 |
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Net sales | $ | 599,310 | $ | 520,540 | $ | 78,770 | 15 | % | |||||||||||||||
▪
$114.1 million of higher sales volume, driven by some customers accelerating orders under long-term commitments in hydroxide
▪
$50.6 million of unfavorable pricing impacts, primarily in battery- and tech-grade carbonate due to lower contract pricing
▪
$15.2 million of favorable currency translation resulting from the weaker U.S. Dollar against various currencies
|
|||||||||||||||||||||||
Adjusted EBITDA | $ | 215,877 | $ | 173,173 | $ | 42,704 | 25 | % | |||||||||||||||
▪
Higher sales volume, partially offset by unfavorable pricing impacts
▪
Lower commission expenses in Chile resulting from the lower pricing in Lithium
▪
Productivity improvements and a reduction in professional fees and other administrative costs
▪
Lower equity in net income of unconsolidated investments from the Talison joint venture
▪
$6.9 million of unfavorable currency translation resulting from a stronger Chilean Peso
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Net sales | $ | 560,195 | $ | 464,371 | $ | 95,824 | 21 | % | |||||||||||||||
▪
$60.0 million of higher sales volume related to increased demand across all products
▪
$28.2 million of favorable pricing impacts, primarily in the flame retardants division and as a result of a favorable 2021 customer mix
▪
$7.6 million of favorable currency translation resulting from the weaker U.S. Dollar against various currencies
|
|||||||||||||||||||||||
Adjusted EBITDA | $ | 187,286 | $ | 156,303 | $ | 30,983 | 20 | % | |||||||||||||||
▪
Higher sales volume and favorable pricing impacts as a result of a favorable 2021 customer mix
▪
Productivity improvements and a reduction in professional fees and other administrative costs
▪
Increased production and utility costs of approximately $6 million resulting from the U.S. Gulf Coast winter storm
▪
Increased freight costs
▪
$6.9 million of favorable currency translation resulting from the weaker U.S. Dollar against various currencies
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Net sales | $ | 368,587 | $ | 404,260 | $ | (35,673) | (9) | % | |||||||||||||||
▪
$38.2 million of lower sales volume, primarily from lower demand in clean fuel technologies
▪
$4.7 million of unfavorable pricing impacts, primarily in FCC
▪
$7.2 million of favorable currency translation resulting from the weaker U.S. Dollar against various currencies
|
|||||||||||||||||||||||
Adjusted EBITDA | $ | 46,591 | $ | 70,247 | $ | (23,656) | (34) | % | |||||||||||||||
▪
Lower sales volume, primarily from lower demand in clean fuel technologies, as well as unfavorable pricing impacts, primarily in FCC
▪
Increased production and utility costs of approximately $17 million resulting from the U.S. Gulf Coast winter storm
▪
Increased freight costs
▪
Partially offset by productivity improvements and a reduction in professional fees and other administrative costs
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Net sales | $ | 75,095 | $ | 113,723 | $ | (38,628) | (34) | % | |||||||||||||||
▪
Primarily decreased volume resulting from the sale of the FCS business in the second quarter of 2021
|
|||||||||||||||||||||||
Adjusted EBITDA | $ | 29,858 | $ | 41,422 | $ | (11,564) | (28) | % | |||||||||||||||
▪
Primarily decreased volume resulting from the sale of the FCS business in the second quarter of 2021
|
In thousands | YTD 2021 | YTD 2020 | $ Change | % Change | |||||||||||||||||||
Adjusted EBITDA | $ | (54,930) | $ | (59,587) | $ | 4,657 | 8 | % | |||||||||||||||
▪
$7.2 million of favorable currency exchange impacts, including a $2.6 million decrease in foreign currency impacts from our Talison joint venture
▪
Productivity improvements and a reduction in professional fees and other administrative costs
|
Issue Month/Year | Principal (in millions) | Interest Rate | Interest Payment Dates | Maturity Date | |||||||||||||||||||||||||
November 2019 | €371.7 | 1.125% | November 25 | November 25, 2025 | |||||||||||||||||||||||||
November 2019 | €500.0 | 1.625% | November 25 | November 25, 2028 | |||||||||||||||||||||||||
November 2019
(a)
|
$171.6 | 3.45% | May 15 and November 15 | November 15, 2029 | |||||||||||||||||||||||||
November 2014
(a)
|
$425.0 | 4.15% | June 1 and December 1 | December 1, 2024 | |||||||||||||||||||||||||
November 2014
(a)
|
$350.0 | 5.45% | June 1 and December 1 | December 1, 2044 |
Maturities of Long-term Debt | Expected Interest Payments | ||||||||||
Remainder of 2021 | $ | 0.6 | $ | 36.3 | |||||||
2022 | — | 57.4 | |||||||||
2023 | — | 57.4 | |||||||||
2024 | 425.0 | 55.9 | |||||||||
2025 | 450.1 | 39.3 | |||||||||
Thereafter | 1,183.8 | 413.7 |
$ in thousands |
Six Months Ended
June 30, 2021 |
Year Ended December 31, 2020 | |||||||||
Net sales
(a)
|
$ | 752,132 | $ | 1,621,651 | |||||||
Gross profit | 151,181 | 357,431 | |||||||||
Income (loss) before income taxes and equity in net income of unconsolidated investments
(b)(c)
|
299,183 | (205,486) | |||||||||
Net income (loss) attributable to the Parent Guarantor and the Issuer | 218,294 | (222,097) |
$ in thousands |
June 30, 2021
|
December 31, 2020 | |||||||||
Current assets
(a)
|
$ | 1,264,129 | $ | 1,194,278 | |||||||
Net property, plant and equipment | 2,714,368 | 2,621,012 | |||||||||
Other noncurrent assets | 525,381 | 305,544 | |||||||||
Current liabilities
(b)
|
$ | 1,362,313 | $ | 2,236,233 | |||||||
Long-term debt | 995,480 | 1,321,413 | |||||||||
Other noncurrent liabilities
(c)
|
7,324,745 | 7,317,103 |
$ in thousands |
Six Months Ended
June 30, 2021 |
Year Ended December 31, 2020 | |||||||||
Net sales
(a)
|
$ | 752,132 | $ | 1,621,651 | |||||||
Gross profit | 160,039 | 375,138 | |||||||||
Income (loss) before income taxes and equity in net income of unconsolidated investments
(b)
|
326,656 | (124,464) | |||||||||
Net income (loss) attributable to the Subsidiary Guarantor and the Parent Issuer | 240,798 | (152,509) |
$ in thousands |
June 30, 2021
|
December 31, 2020 | |||||||||
Current assets
(a)
|
$ | 1,122,126 | $ | 1,315,110 | |||||||
Net property, plant and equipment | 721,928 | 770,230 | |||||||||
Other non-current assets
(b)
|
1,553,934 | 970,268 | |||||||||
Current liabilities
(c)
|
$ | 1,323,229 | $ | 2,133,548 | |||||||
Long-term debt | 1,808,445 | 2,404,193 | |||||||||
Other noncurrent liabilities
(c)
|
6,612,424 | 6,468,644 |
Item 3. | Quantitative and Qualitative Disclosures About Market Risk. |
Item 4. | Controls and Procedures. |
Item 1. | Legal Proceedings. |
Item 1A. | Risk Factors. |
Item 6. | Exhibits. |
101 |
Interactive Data File (Quarterly Report on Form 10-Q, for the quarterly period ended June 30, 2021, furnished in XBRL (eXtensible Business Reporting Language)).
|
# | Management contract or compensatory plan or arrangement. | ||||
* | Included with this filing. |
ALBEMARLE CORPORATION | |||||||||||||||||
(Registrant) | |||||||||||||||||
Date: | August 4, 2021 | By: |
/
S
/ S
COTT
A. T
OZIER
|
||||||||||||||
Scott A. Tozier | |||||||||||||||||
Executive Vice President and Chief Financial Officer | |||||||||||||||||
(principal financial officer) |
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|
No information found
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|